-
r37980778c78--4f86da1d27cd916cd0a30f0b753c2985
ObjectiveThis trial was conducted to evaluate the ability of pazopanib to overcome therapeutic 131I resistance.Materials, methods and patientsThis phase 1 trial assesses the... -
Demographic data
**P<0.01; SD, standard deviation; Max/Min, maximal/minimal.The number of participants did not differ between genders (Chi-square P>0.05). The dancer and pianist groups... -
Univariate cox regression analysis for NDMM cohort.
Univariate cox regression analysis for NDMM cohort. -
r37980778c78--24969f8ec0eb81eb238745d7dc283894
Factors associated with severity of MTX-related pancytopenia (n = 31). -
r37980778c78--542a88f68d4312fba647bb4c4963016a
Clinical outcomes in medical and surgical arms at 12 months of follow-up. -
Research and Development of Hepatitis B Drugs: An Analysis Based on Technolog...
Despite the existence of available therapies, the Hepatitis B virus infection continues to be one of the most serious threats to human health, especially in developing countries... -
Information of the main technology clusters in the patent citation network<su...
Information of the main technology clusters in the patent citation networka. -
Herbs frequently used and common traditional Korean medicine diagnostic categ...
Herbs frequently used and common traditional Korean medicine diagnostic categories. -
r37980778c78--c85cfd788d440102ddfa5fc6b87e00c3
Results of Bayesian NMAs of exacerbations, mortality, and adverse events according to the drug class. -
r37980778c78--91d5aba918cab8be0b4d27ce0f77117d
Number of adverse effects in the medical and surgical treatment within 12 months of treatment. -
r37980778c78--bdd43b3703e58bb8260eab508bcdc0bb
BackgroundRadiation pneumonitis is a common and serious complication of radiotherapy. Many published randomized controlled studies (RCTs) reveal a growing trend of using herbal... -
Themes and sub-themes identified, with example quotations.
Themes and sub-themes identified, with example quotations. -
Patient’s demographics and clinical characteristics (n = 362).
Patient’s demographics and clinical characteristics (n = 362). -
Model parameters.
aSpecified with reference to Cook [30] and Waage et al. [36] using distributions defined in Biosecurity Australia [31]; b Derived from Sapoukhina et al. [37]; c ABS [6], Note... -
r37980778c78--e77c9b2032a2d01deb19976bd4b24c7d
Probability of escalation to the next higher dose for each underlying true DLT rate. -
Characteristics of included studies (2,911 participating GPs).
Characteristics of included studies (2,911 participating GPs).
